日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism

组蛋白去乙酰化酶活性通过非基因组机制调控舒张功能障碍。

Jeong, Mark Y; Lin, Ying H; Wennersten, Sara A; Demos-Davies, Kimberly M; Cavasin, Maria A; Mahaffey, Jennifer H; Monzani, Valmen; Saripalli, Chandrasekhar; Mascagni, Paolo; Reece, T Brett; Ambardekar, Amrut V; Granzier, Henk L; Dinarello, Charles A; McKinsey, Timothy A

Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat

在杜氏肌营养不良症的mdx小鼠模型中,使用组蛋白去乙酰化酶抑制剂givinostat进行了临床前研究。

Consalvi, Silvia; Mozzetta, Chiara; Bettica, Paolo; Germani, Massimiliano; Fiorentini, Francesco; Del Bene, Francesca; Rocchetti, Maurizio; Leoni, Flavio; Monzani, Valmen; Mascagni, Paolo; Puri, Pier Lorenzo; Saccone, Valentina

Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat)

口服组蛋白去乙酰化酶抑制剂 ITF2357(givinostat)1 期试验期间的药代动力学、安全性和可诱导细胞因子反应

Antonio Furlan, Valmen Monzani, Leonid L Reznikov, Flavio Leoni, Gianluca Fossati, Daniela Modena, Paolo Mascagni, Charles A Dinarello